PMID- 35391537
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220421
IS  - 2211-9132 (Print)
IS  - 2211-9140 (Electronic)
IS  - 2211-9132 (Linking)
VI  - 41
IP  - 2
DP  - 2022 Mar
TI  - GLP-1 receptor agonists in diabetic kidney disease: current evidence and future 
      directions.
PG  - 136-149
LID - 10.23876/j.krcp.22.001 [doi]
AB  - With the emergence of various classes of blood glucose-lowering agents, choosing 
      the appropriate drug for each patient is emphasized in diabetes management. Among 
      incretin-based drugs, glucagon-like peptide 1 (GLP-1) receptor agonists are a 
      promising therapeutic option for patients with diabetic kidney disease (DKD). 
      Several cardiovascular outcome trials have demonstrated that GLP-1 receptor 
      agonists have beneficial effects on cardiorenal outcomes beyond their blood 
      glucose-lowering effects in patients with type 2 diabetes mellitus (T2DM). The 
      renal protective effects of GLP-1 receptor agonists likely result from their 
      direct actions on the kidney, in addition to their indirect actions that improve 
      conventional risk factors for DKD, such as reducing blood glucose levels, blood 
      pressure, and body weight. Inhibition of oxidative stress and inflammation and 
      induction of natriuresis are major renoprotective mechanisms of GLP-1 analogues. 
      Early evidence from the development of dual and triple combination agents 
      suggests that GLP-1 receptor agonists will probably become popular treatment 
      options for patients with T2DM.
FAU - Yu, Ji Hee
AU  - Yu JH
AD  - Division of Endocrinology and Metabolism, Department of Internal Medicine, Korea 
      University Ansan Hospital, Korea University College of Medicine, Ansan, Republic 
      of Korea.
FAU - Park, So Young
AU  - Park SY
AD  - Division of Endocrinology and Metabolism, Department of Internal Medicine, Korea 
      University Ansan Hospital, Korea University College of Medicine, Ansan, Republic 
      of Korea.
FAU - Lee, Da Young
AU  - Lee DY
AD  - Division of Endocrinology and Metabolism, Department of Internal Medicine, Korea 
      University Ansan Hospital, Korea University College of Medicine, Ansan, Republic 
      of Korea.
FAU - Kim, Nan Hee
AU  - Kim NH
AD  - Division of Endocrinology and Metabolism, Department of Internal Medicine, Korea 
      University Ansan Hospital, Korea University College of Medicine, Ansan, Republic 
      of Korea.
FAU - Seo, Ji A
AU  - Seo JA
AD  - Division of Endocrinology and Metabolism, Department of Internal Medicine, Korea 
      University Ansan Hospital, Korea University College of Medicine, Ansan, Republic 
      of Korea.
LA  - eng
GR  - 2018R1D1A1B07049123/National Research Foundation of Korea/
GR  - 2020R1F1A1074265/National Research Foundation of Korea/
GR  - K1824431/Korea University/
PT  - Journal Article
DEP - 20220325
PL  - Korea (South)
TA  - Kidney Res Clin Pract
JT  - Kidney research and clinical practice
JID - 101586778
PMC - PMC8995488
OTO - NOTNLM
OT  - Diabetic nephropathies
OT  - Glucagon-like peptide 1
OT  - Type 2 diabetes mellitus
COIS- Conflicts of interest All authors have no conflicts of interest to declare.
EDAT- 2022/04/09 06:00
MHDA- 2022/04/09 06:01
PMCR- 2022/03/01
CRDT- 2022/04/08 02:54
PHST- 2021/12/29 00:00 [received]
PHST- 2022/02/22 00:00 [accepted]
PHST- 2022/04/08 02:54 [entrez]
PHST- 2022/04/09 06:00 [pubmed]
PHST- 2022/04/09 06:01 [medline]
PHST- 2022/03/01 00:00 [pmc-release]
AID - j.krcp.22.001 [pii]
AID - j-krcp-22-001 [pii]
AID - 10.23876/j.krcp.22.001 [doi]
PST - ppublish
SO  - Kidney Res Clin Pract. 2022 Mar;41(2):136-149. doi: 10.23876/j.krcp.22.001. Epub 
      2022 Mar 25.